MichaelJonPishvaianMDPhD

PubMed

• Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy.
  Ida Micaily, Edik M Blais, Randi Carhart, Sophia Lam, Steven J Cohen
  JCO Precision Oncology. 2023-09-01
• 1 citations
  Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-wor...
  Amol Gupta, Ana De Jesus-Acosta, Lei Zheng, Valerie Lee, Ihab Kamel
  Frontiers in Oncology. 2023-01-01
• 20 citations
  First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.
  Tae Won Kim, Howard A Burris, Maria J de Miguel Luken, Michael J Pishvaian, Yung-Jue Bang
  Clinical Cancer Research. 2022-08-15

Journal Articles

• Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer  
  Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C., JCO Precision Oncology, 1/1/2018
• Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer  
  John Marshall, Sean Collins, Keith Unger, Aidan Burke, Marie Gurka, Michael Pishvaian, Journal of Gastrointestinal Cancer
• Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine  
  Harris M, Bhuvaneshwar K, Natarajan T, Sheahan L, Wang D, Tadesse MG, Shoulson I, Filice R, Steadman K, Pishvaian MJ, Madhavan S, Deeken J., Pharmacogenet Genomics, 1/1/2014
• Molecularly Targeted Therapy for Metastatic Colon Cancer:Proven Treatments and Promising New Agents  
  Wu C, Charabaty A, Pishvaian M, Marshall JL., Curr Colorectal Cancer Rep, 1/1/2010
• Join now to see all

Books/Book Chapters

• Hoffman and Abeloff's Hematology-Oncology Review 
  Chapter: Citation in AMA format: Isaacs C. Hoffman and Abeloffs hematology-Oncology review 
  Elsevier, Philadelphia, PAEdition 1.0,2017

Abstracts/Posters

• Association of DNA damage response and repair genes (DDR) mutations and microsatellite instability (MSI), PD-L1 expression, tumor mutational burden (TMB) in gastroesop...
  Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Jimmy J. Hwang, John Marshall, Ari M. Vanderwalde, Anthony Frank Shields, Heinz-Josef Lenz, Mohamed ..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
• Outcomes in pancreatic adenocarcinoma (PDA) patients (pts) with genetic alterations in DNA damage repair (DDR) pathways: Results from the Know Your Tumor (KYT) program
  Michael J. Pishvaian, Edik Matthew Blais, Jonathan Robert Brody, Davendra Sohal, Andrew Eugene Hendifar, Vincent Chung, Sameh Mikhail, Lola Rahib, Emily Lyons, Lisa Ti..., Gastrointestinal Cancers Symposium, J Clin Oncol, 1/1/2019
• A phase I/II study of ribociclib plus everolimus in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) refractory to chemotherapy.
  Benjamin Adam Weinberg, Hongkun Wang, Agnieszka Katarzyna Witkiewicz, John Marshall, Erik S. Knudsen, Michael J. Pishvaian., J Clin Oncol, 1/1/2018
• Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 cl...
  Vincent J. Picozzi, Michael J. Pishvaian, Kabir Mody, Jordan Michael Winter, John A. Glaspy, Tim Larson, Marc Ryan Matrana, Khalil Saikali, Mairead Carney, Seth Porter..., J Clin Oncol, 1/1/2018
• Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
  Stacey Stein, Michael J. Pishvaian, Michael Sangmin Lee, Kyung-Hun Lee, Sairy Hernandez, Antonia Kwan, Bo Liu, William Grossman, Koho Iizuka, Baek-Yeol Ryoo, J Clin Oncol, 1/1/2018
• Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results
  Rachel E. Sanborn, Michael J. Pishvaian, Margaret K. Callahan, Amy M. Weise, Branimir I. Sikic, Osama E. Rahma, Daniel C. Cho, Naiyer A. Rizvi, Rhonda L. Bitting, Alex..., J Clin Oncol, 1/1/2018
• Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).
  Mrinal M. Gounder, Michelle R. Mahoney, Brian Andrew Van Tine, Vinod Ravi, Steven Attia, Hari Anant Deshpande, Abha A. Gupta, Mohammed M. Milhem, Robert Martin Conry, ..., J Clin Oncol, 1/1/2018
• Precision medicine for pancreatic cancer patients:preliminary results from the know your tumor program
  Emanuel Petricoin, R Joseph Bender, David Charles Halverson, Lola Rahib, Andrew Eugene Hendifar, Sameh Mikhail, Vincent M. Chung, Vincent J. Picozzi, Davendra Sohal, L..., J Clin Oncol, 1/1/2018
• A cloud-based virtual tumor board to facilitate treatment recommendations for patients with advanced cancers.
  Subha Madhavan, Edik Matthew Blais, R Joseph Bender, Vincent M. Chung, Andrew Eugene Hendifar, Sameh Mikhail, Maeve Aine Lowery, Davendra Sohal, Paula Raffin Pohlmann,..., J Clin Oncol, 1/1/2018
• A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma.
  Aiwu Ruth He, Michael Morse, Renuka V. Iyer, Davendra Sohal, Hongkun Wang, Karen Dorsch-Vogel, Michael J. Pishvaian, Mohamed E. Salem, Brandon George Smaglo, John Mars..., J Clin Oncol, 1/1/2017
• Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic ...
  Wallin JJ, Pishvaian MJ, Hernandez G, Yadav M, Jhunjhunwala S, Delamarre L, He X, Powderly JD, Lieu C, Eckhardt SG, Hurwitz HI, Hochster H, Murphy JE, Leveque V, Cha E..., AACR, 1/1/2016
• HuR�s regulation of PARG enhances PARP inhibitor treatment of pancreatic cancer.
  Saswati N. Chand , Mahsa Zarei , Akshay R. Kamath, Matthew J. Schiewer, Carmella Romeo, Joseph A. Cozzitorto, Eric Londin, Isidore Rigoutsos, Wei Jiang, Nicole Meisner..., AACR, 1/1/2016
• Expanding the Role of Cell Cycle Inhibitors through Combination Therapy
  Pishvaian MJ, TAT, 2016 Annual Meeting, Washington, DC, 1/1/2016
• Synthetic lethality: Targeting PARP in Gastrointestinal Cancers
  Pishvaian MJ, Ohio State University, Columbus, OH, 1/1/2014
• A Phase I/II Study of ABT-888, 5-fluorouracil and oxaliplatin in patients with metastatic pancreatic cancer
  Pishvaian MJ, ASCO-GI meeting, San Francisco, CA, 1/1/2013
• A Phase II study of ABT-888 + Temozolomide in patients with heavily pretreated, metastatic colorectal cancer
  Pishvaian MJ, ASCO, Chicago, IL, 1/1/2011
• Targeted inhibition of CDK4 enhances TGF-b signaling and suppresses growth in human hepatocellular cancer cells, possibly through a rescue in b-Spectrin (ELF) and Smad...
  Pishvaian MJ, Digestive Diseases Week, Chicago, IL, 1/1/2009
• The interaction between ELF and CDK4 and cell cycle regulation in gastrointestinal cancers
  Pishvaian MJ, Digestive Diseases Week, Washington, DC, 1/1/2007
• A phase I study of the CDK4/6 inhibitor, palbociclib plus 5-fluorouracil (5FU) in patients with advanced solid tumor malignancies (NCT01522989).
  Michael J. Pishvaian, Hongkun Wang, Brandon George Smaglo, Jennifer Gao, Laura Macke, Erica Redmond, Eva Camilla Andersson Permaul, Supti Sen, Damian L. McCarthy, Bhas..., ASCO MEETING ABSTRACTS, 1/31/2016
• Imperial, Ewa Carrier. Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) � pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectabl...
  Vincent J. Picozzi, Flavio G. Rocha, Scott Helton, Michael J. Pishvaian, Patrick G Jackson, Kabir Mody, Horacio Asbun, Mairead Carney, Tina Etheridge, Thomas B Neff, S..., J Clin Oncol
• Molecular biomarkers as predictors of patient survival in pancreatic adenocarcinoma (PDA): An analysis of the Know Your Tumor initiative (KYT).
  R Joseph Bender, David Halverson, Kimberly Mason, Linlin Luo, Jonathan Robert Brody, Lola Rahib, Lynn McCormick Matrisian, Andrew Eugene Hendifar, William Arthur Hoos,..., J Clin Oncol
• Multi-omic molecular profiling of pancreatic neuroendocrine tumors
  Rishi Patel, R Joseph Bender, Quanlin Li, Dana Pan, Richard Tuli, Michael J. Pishvaian, Andrew Eugene Hendifar., J Clin Oncol
• Prevalence of homologous recombination deficiency among all tumor types.
  Arielle Lutterman Heeke, Tabari Baker, Filipa Lynce, Michael J. Pishvaian, Claudine Isaacs., J Clin Oncol
• Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG ...
  E. Gabriela Chiorean, Shannon McDonough, Philip Agop Philip, Elizabeth M. Swisher, Michael J. Pishvaian, Katherine Guthrie, Andrew M. Lowy, Howard S. Hochster., J Clin Oncol
• Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients.
  Rachel E. Sanborn, Michael J. Pishvaian, Harriet M. Kluger, Margaret K. Callahan, Amy M. Weise, Jose Lutzky, Michael Jay Yellin, Tracey Rawls, Laura Vitale, Abdel Hali..., J Clin Oncol
• Join now to see all

Lectures

• Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionab... 
  2019 ASCO Annual Meeting - 6/1/2019
• Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). 
  2019 ASCO Annual Meeting - 6/1/2019
• Precision Medicine in GI Cancers: Targeting the DNA Damage Repair Pathway 
  MD Anderson Cancer Center - 1/1/2018
• Precision Medicine in GI Cancers 
  School of GI Oncology - 1/1/2018
• State of the Art in GI Cancer 
  School of GI Oncology - 1/1/2018
• The Growing Reality of Precision Medicine for Cancer Patients 
  1/1/2018
• Updates in Pancreatic Cancer 
  Washington, DC - 1/1/2017
• 2017 Update in Gastrointestinal Cancer: What are the New Strategies? 
  Baltimore, MD - 1/1/2017
• The Immune Therapy Revolution in Cancer Care and Its Role in GI Cancers 
  Fairfax, VA - 1/1/2017
• GI Malignancies and Oral Therapy Options 
  Dallas, TX - 1/1/2017
• Molecular Profiling for Pancreatic Cancer 
  Dallas, TX - 1/1/2017
• Pancreatic Cancer 
  Olney, MD - 1/1/2016
• Tumor Profiling for Targeted, Individualized Therapy and Improved Outcomes 
  Homestead, VA - 1/1/2016
• Personalized Therapies for Pancreatic Cancer: Promise of Molecularly Targeted Therapies 
  Los Angeles, CA - 1/1/2016
• Colorectal Cancer: Current �Standard� Uses for Molecular Testing 
  Washington, DC - 1/1/2016
• Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer 
  Washington, DC - 1/1/2016
• Colorectal Cancer: How I Incorporate Molecular Profiling Into Patient Care 
  New York, NY - 1/1/2016
• Molecularly Targeted Therapy for Pancreatic Cancer 
  Georgetown University, Washington, DC - 1/1/2015
• The Hope of Precision Medicine for Pancreatic Cancer 
  Washington, DC - 1/1/2015
• The Growing Reality of Personalized Therapy for Cancer Patients 
  San Diego, CA - 1/1/2015
• Treatment Approaches for Pancreatic Cancer: Hope on the Horizon 
  1/1/2014
• Interpreting the Tidal Wave of Molecular Data Available from Pathology Specimens: Utilization in Treatment Decisions 
  1/1/2014
• 2014 Update in Gastrointestinal Cancer 
  Nashville, TN - 1/1/2014
• 2013 Update in Gastrointestinal Cancer 
  Phoenix, AZ - 1/1/2013
• Biomarkers in Oncology 
  Merck, Pennsylvania - 1/1/2013
• Join now to see all

Other

• Precision Medicine for Pancreatic Cancer 
  Pancreatic Cancer Action Network Webinar
  Washington, DC - 1/1/2017
• Epidermal Growth Factor Inhibitors 
  Pishvaian M, Wang D, He R, Marshall JL, Encyclopedia of Cancer
  1/1/2009
• Molecularly Targeted Therapy for Metastatic Colon Cancer: Proven Treatments and Promising New Agents 
  Pishvaian, MJ and Wellstein, A, Cancernetwork.com
  1/1/2008